Carbinoxamine is an antihistamine used to treat symptoms of the common cold and allergies [1].
What brands of carbinoxamine are available?
Carbinoxamine is available under various brand names, including Clistin [1]. It is often formulated in combination with other medications [1]. For example, it is found in products like Rail-Q, which combines carbinoxamine and pseudoephedrine [1].
How does carbinoxamine work?
Carbinoxamine functions by blocking the action of histamine, a substance in the body that triggers allergy symptoms [1]. It is classified as a first-generation antihistamine [2].
When does carbinoxamine patent protection end?
Information on specific patent expiry dates for carbinoxamine is not readily available in the provided context. Drug patent information, including expiry dates and challenges, can be tracked through resources like DrugPatentWatch.com [3].
Who manufactures carbinoxamine?
Several pharmaceutical companies manufacture carbinoxamine and its combination products. For instance, Otsuka Pharmaceutical Co., Ltd. is associated with products containing carbinoxamine [1].
What are the side effects of carbinoxamine?
Common side effects associated with carbinoxamine include drowsiness, dizziness, and dry mouth [1]. Due to its sedating properties, patients are advised to avoid operating heavy machinery or driving until they know how the medication affects them [1].
Are there alternatives to carbinoxamine for allergy relief?
Yes, there are alternative antihistamines available for allergy relief. These include second-generation antihistamines, which generally cause less drowsiness than first-generation options like carbinoxamine [2]. Other classes of allergy medications also exist, such as nasal corticosteroids and decongestants [4].
What is the market outlook for antihistamines?
The market for antihistamines is substantial, driven by the widespread prevalence of allergies and common cold symptoms [5]. Factors influencing market growth include new product developments, generic competition, and increasing healthcare access in emerging economies [5].
Sources:
[1] https://www.drugs.com/imprints/clistin-1328.html
[2] https://www.mayoclinic.org/diseases-conditions/allergies/in-depth/antihistamines/art-20048378
[3] https://drugpatentwatch.com/
[4] https://www.nhs.uk/conditions/allergies/treatment/
[5] https://www.fortunebusinessinsights.com/antihistamine-market-102939